Somewhat Negative Media Coverage Extremely Likely to Impact Cronos Group (CRON) Stock Price
News articles about Cronos Group (NASDAQ:CRON) have been trending somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than 6,000 news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cronos Group earned a news sentiment score of -1.08 on their scale. InfoTrie also assigned news stories about the company an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Cronos Group’s score:
- Cronos Group (CRON) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS (americanbankingnews.com)
- Pi Financial Reiterates Neutral Rating for Cronos Group (CRON) (americanbankingnews.com)
- Stock Market Today: Bed Bath & Beyond Soars on Activist Plans (finance.yahoo.com)
- Cronos Group Inc (CRON) Q4 2018 Earnings Conference Call Transcript (finance.yahoo.com)
- Cannabis producer Cronos sinks after revenue comes up short (businessinsider.com)
NASDAQ CRON opened at $20.24 on Wednesday. Cronos Group has a one year low of $5.12 and a one year high of $25.10. The company has a market capitalization of $3.62 billion and a PE ratio of 2,024.00.
A number of research firms recently commented on CRON. Canaccord Genuity cut shares of Cronos Group from a “hold” rating to a “sell” rating and set a $17.00 price target for the company. in a research note on Wednesday. Pi Financial reaffirmed a “neutral” rating and issued a $24.00 price target on shares of Cronos Group in a research report on Tuesday. Zacks Investment Research cut shares of Cronos Group from a “hold” rating to a “sell” rating in a research report on Wednesday, December 12th. BMO Capital Markets lowered shares of Cronos Group from a “market perform” rating to an “underperform” rating and set a $21.43 price objective for the company. in a research note on Monday, March 11th. They noted that the move was a valuation call. Finally, Eight Capital lowered shares of Cronos Group to a “hold” rating in a research note on Thursday, March 7th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $15.24.
ILLEGAL ACTIVITY WARNING: “Somewhat Negative Media Coverage Extremely Likely to Impact Cronos Group (CRON) Stock Price” was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/somewhat-negative-media-coverage-extremely-likely-to-impact-cronos-group-cron-stock-price/2920832.html.
Cronos Group Company Profile
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada.
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.